Anabolic Agents and the Body: The Pharmacology of Performance, Without Myths - Episode 4: Estrogen, Aromatization and Hormonal Balance

1. Estrogen is not testosterone's enemy

Estradiol is an active and important hormone in men. Part of it is produced through aromatization of androgens and it contributes to bone, brain, sexual function and endocrine regulation.

2. What aromatase is

Aromatase, the enzyme encoded by CYP19A1, converts androgens into estrogens. Testosterone can be converted to estradiol, while androstenedione can become estrone.

3. Where aromatization occurs

Aromatase is present in several tissues, including adipose tissue, bone, brain and gonads. Circulating estradiol does not depend exclusively on the testes.

4. Testosterone has several pathways

Testosterone can act through the androgen receptor, become DHT through 5-alpha-reductase, or be aromatized to estradiol. The final effect depends on tissue, receptors and enzymes.

5. Estradiol and bone health

Estradiol has an important role in male bone metabolism. Estrogen deficiency can affect bone mineral density and remodeling.

6. Estradiol and sexual function

Estradiol contributes to libido and sexual function and interacts with testosterone in the nervous system and peripheral tissues.

7. Exogenous testosterone and aromatization

More available testosterone can provide more substrate for aromatase. In some contexts, estradiol rises with exogenous androgens while HPG feedback suppresses endogenous production.

8. Adipose tissue and aromatase

Adipose tissue is an important site of peripheral aromatization. Body composition can influence the estrogenic environment, but the relationship is not simple enough to predict an individual's estradiol level.

9. There is no magic testosterone-to-estradiol ratio

A perfect T:E2 ratio is an online simplification. Values should be interpreted with symptoms, clinical context and laboratory method.

10. Zero estrogen is not a goal

Excessive reduction of estradiol can have negative consequences, including effects on bone and sexual function. Less estrogen does not automatically mean healthier or better performance.

11. Gynecomastia and hormonal signaling

Gynecomastia reflects interactions between estrogenic and androgenic signaling, tissue sensitivity and duration of exposure.

12. Aromatase is a normal physiological pathway

Conversion of testosterone to estradiol is part of normal androgen metabolism and produces a hormone with its own biological functions.

13. Estradiol and HPG feedback

Estradiol contributes to negative feedback on the hypothalamus and pituitary and participates in regulation of GnRH, LH and FSH.

14. What hormonal balance means

Hormonal balance means a functional relationship between production, feedback, conversion and tissue action, not elimination of one hormone.

15. What matters for a strength athlete

Strength and muscle mass are not determined by one hormone. Training, energy availability, sleep, stress, the nervous system and connective tissue all matter.

16. Why laboratory method matters

Estradiol can be difficult to measure accurately at concentrations commonly found in men, and assays are not equivalent. Results require context.

17. Aromatase inhibition is not a universal solution

Reducing conversion of androgens to estrogens is not automatically beneficial. Hormonal interventions require medical assessment.

18. After stopping exogenous androgens

After exposure stops, the body must gradually reactivate the HPG axis. Recovery varies between individuals.

19. Common myths

High estrogen does not automatically explain every symptom, and low estrogen does not automatically mean better performance. Causes may be multiple.

20. Conclusion

Estrogen is not testosterone's enemy. Aromatase is a normal physiological pathway, and endocrine balance depends on the interaction between androgens, estrogens, central feedback and tissues.

Editorial note: this article explains biological mechanisms and risks associated with exogenous androgens. It does not provide doses, cycles or use protocols.

References: Finkelstein JS et al., N Engl J Med, PMID 22611112; Falahati-Nini A et al., J Clin Endocrinol Metab, PMID 10522996; Hammond GL et al., Eur J Endocrinol, PMID 31096185; Simpson ER et al., Annu Rev Physiol, PMID 17333210; LeBlanc ES et al., J Clin Endocrinol Metab, PMID 15579733; Swislocki AL, Eisenberg ML, World J Mens Health, 2025, PMID 39344113.